Tejal Patel, MD

Assistant Professor of Clinical Medicine in Oncology, Institute for Academic Medicine
Assistant Clinical Member, Research Institute
Houston Methodist
Weill Cornell Medical College


Biography

Dr. Patel earned her medical degree from the University of Texas Medical Branch at Galveston in 2003. She completed residency and fellowship training at Mayo Graduate School of Medicine in Jacksonville, Florida. She held a faculty appointment at the Mayo Graduate School of Medicine before joining the Methodist Cancer Center in 2012 as director of the high risk clinic. As a member of the HMRI Cancer Research Program, she directs research focusing on breast cancer and breast cancer prevention. Dr. Patel has published several articles in peer reviewed journals.

Description of Research

Dr. Patel’s research program focuses on identifying and treating patients at high risk of breast cancer. Current research efforts aim to address the limitations of treatments currently available for prevention. Dr. Patel and her research team are developing clinical trials for compounds with less toxicity that can provide better compliance. She is also collaborating with her scientific partners to explore new ways of delivering currently approved treatments for breast cancer.

Areas Of Expertise

Breast cancer Breast cancer prevention
Publications

Correlating mammographic and pathologic findings in clinical decision support using natural language processing and data mining methods
Patel, TA, Puppala, M, Ogunti, RO, Ensor, JE, He, T, Shewale, JB, Ankerst, DP, Kaklamani, VG, Rodriguez, AA, Wong, STC & Chang, JC 2016, Cancer. DOI:

Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients
Liang, DH, Ensor, JE, Liu, Z-B, Patel, A, Patel, TA, Chang, JC & Rodriguez, AA 2016, Breast Cancer Research and Treatment, vol 155, no. 1, pp. 139-49. DOI:

Correlating mammographic and pathologic findings in clinical decision support using natural language processing and data mining methods
Patel, TA, Puppala, M, Ogunti, RO, Ensor, Jr. JE, He, T, Shewale, JB, Ankerst, DP, Kaklamani, VG, Rodriguez, AA, Wong, STC & Chang, JC 2016, Cancer. DOI:

Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients
Liang, DH, Ensor, JE, Liu, ZB, Patel, A, Patel, TA, Chang, JC & Rodriguez, AA 2016, Breast Cancer Research and Treatment, vol 155, no. 1, pp. 139-149. DOI:

Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer
Granados-Principal, S, Liu, Y, Guevara, ML, Blanco, E, Choi, DS, Qian, W, Patel, T, Rodriguez, AA, Cusimano, J, Weiss, HL, Zhao, H, Landis, MD, Dave, B, Gross, SS & Chang, JC 2015, Breast Cancer Research, vol 17, no. 1, 25. DOI:

Erratum: Dual HER2 blockade: Preclinical and clinical data
Patel, TA , Dave, B , Rodriguez, AA , Chang, JC, Perez, EA & Colon-Otero, G 2014, Breast Cancer Research. DOI:

Dual HER2 blockade: Preclinical and clinical data
Patel, TA , Dave, B , Rodriguez, AA , Chang, JC, Perez, EA & Colon-Otero, G 2014, Breast Cancer Research, vol 16, no. 4, 419. DOI:

RC0639: Phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer
Moreno-Aspitia, A, Dueck, AC, Ghanem-Cañete, I, Patel, T, Dakhil, S, Johnson, D, Franco, S, Kahanic, S, Colon-Otero, G, Tenner, KS, Rodeheffer, R, McCullough, AE, Jenkins, RB, Palmieri, FM, Northfelt, D & Perez, EA 2013, Breast Cancer Research and Treatment, vol 138, no. 2, pp. 427-435. DOI:

Metastatic breast cancer
Patel, TA & Perez, EA 2010, . in Management of Breast Diseases. Springer Berlin Heidelberg, pp. 425-449. DOI:

Erratum: Changes to adjuvant systemic therapy in breast cancer: A decade in review (Clinical Breast Cancer (2010) 10:3 (196-208) DOI: 10.3816/CBC.2010.n. 027)
Saurel, CA, Patel, TA & Perez, EA 2010, Clinical Breast Cancer, vol 10, no. 5. DOI:

Changes to adjuvant systemic therapy in breast cancer: A decade in review
Saurel, CA, Patel, TA & Perez, EA 2010, Clinical Breast Cancer, vol 10, no. 3, pp. 196-208. DOI:

Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer
Perez, EA, Patel, T & Moreno-Aspitia, A 2010, Breast Cancer Research and Treatment, vol 121, no. 2, pp. 261-271. DOI:

Breast cancer in latinas: Gene expression, differential response to treatments, and differential toxicities in latinas compared with other population groups
Patel, TA, Colon-Otero, G, Hume, CB, Copland, JA & Perez, EA 2010, Oncologist, vol 15, no. 5, pp. 466-475. DOI:

North Central Cancer Treatment Group (NCCTG) N0432: Phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer
Perez, EA, Hillman, DW, Dentchev, T, Le-Lindqwister, NA, Geeraerts, LH, Fitch, TR, Liu, H, Graham, DL, Kahanic, SP, Gross, HM, Patel, TA, Palmieri, FM & Dueck, AC 2009, Annals of Oncology, vol 21, no. 2, mdp512, pp. 269-274. DOI: